Elke Schueler (Elke Schüler)

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 6

Top Topics

Systematic Review

Cardiovascular Risk Factors

Top Venues

Advances in therapy

Diabetes, obesity & metabolism

This page only lists publications with an associated author ORCID identifier.

Publications

Christoph Wanner, Hristo Iliev, Nathalia Duarte, Elke Schueler, Ana Rita Soares, Vikram Thanam, Egon Pfarr
Safety of Empagliflozin: An Individual Participant-Level Data Meta-Analysis from Four Large Trials. Advances in therapy 41 (7) (2024)
Christoph Wanner, Hristo Iliev, Nathalia Duarte, Elke Schueler, Ana Rita Soares, Vikram Thanam, Egon Pfarr
Safety of Empagliflozin: An Individual Participant-Level Data Meta-Analysis from Four Large Trials. Advances in therapy (2024)
Christoph Wanner, Hristo Iliev, Nathalia Duarte, Elke Schueler, Ana Rita Soares, Vikram Thanam, Egon Pfarr
Safety of Empagliflozin: An Individual Participant-Level Data Meta-Analysis from Four Large Trials. Advances in therapy 41 (7) (2024)
Christoph Wanner, Hristo Iliev, Nathalia Duarte, Elke Schueler, Ana Rita Soares, Vikram Thanam, Egon Pfarr
Safety of Empagliflozin: An Individual Participant-Level Data Meta-Analysis from Four Large Trials. Advances in therapy 41 (7) (2024)
Christoph Wanner, Hristo Iliev, Nathalia Duarte, Elke Schueler, Ana Rita Soares, Vikram Thanam, Egon Pfarr
Safety of Empagliflozin: An Individual Participant-Level Data Meta-Analysis from Four Large Trials. Advances in therapy 41 (7) (2024)
Sabine Kahl, Anne Pernille Ofstad, Bernard Zinman, Christoph Wanner, Elke Schueler, Naveed Sattar, Catherine M Viscoli, Michael Roden
Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomes. Diabetes, obesity & metabolism 24 (6) (2022)